cabozantinib,atezolizumab
exelixis,roche
['atezolizumab', 'cabozantinib']
#asco22 cabozantinib + atezolizumab (post io) showed rr 19% , dcr 80%, mdor 5.8m. cabozantinib alone with rr 6% and mdor 10.6m (but only n=2). mpfs 4.5m with combo and 3.4m mono. mos 13.8m with combo and 9.4m mono. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him